Company News

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

12 March 2025

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX(TM) Platform and Next-Generation Nasal COVID-19 Vaccine

16 December 2024

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

10 September 2024

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

23 July 2024

Rocketvax Announces Collaboration with the US National Institutes of Health (NIH) for Clinical Trial of Nasal, Live-Attenuated NextGen SARS-CoV-2 Vaccine

13 June 2024

New study on the benefits of COVID-19 nasal spray vaccination published in "Nature Communications"

27 February 2024

Finanz und Wirtschaft: RocketVax could become the new Moderna

16 November 2023

Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy

14 November 2023

Impfen wir bei Covid-19 bald über die Nase?

7 August 2023

Nasal vaccine against coronavirus further improved

13 June 2023

New vaccine concept against SARS-CoV-2 successfully tested

5 June 2023

Swiss Rockets AG Welcomes Three New Key Members To The Team

18 April 2023

RocketVax Nasal Vaccine to Prevent COVID-19 Passes First Tests

4 April 2023

CNN Health Reports About RocketVax Covid-19 Nasal Vaccine

3 April 2023

RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward

6 February 2023